alkeran 2mg potahovaná tableta
aspen pharma trading limited, dublin array - 1571 melfalan - potahovaná tableta - 2mg - melfalan
alkeran 50mg prášek a rozpouštědlo pro injekční/infuzní roztok
aspen pharma trading limited, dublin array - 1571 melfalan - prášek a rozpouštědlo pro injekční/infuzní roztok - 50mg - melfalan
melphalan zentiva 50mg prášek a rozpouštědlo pro injekční/infuzní roztok
zentiva, k.s., praha array - 21067 melfalan-hydrochlorid - prášek a rozpouštědlo pro injekční/infuzní roztok - 50mg - melfalan
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastická činidla - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.